Moderna Ships First mRNA Vaccines Manufactured in Canada
PorAinvest
lunes, 22 de septiembre de 2025, 8:14 am ET1 min de lectura
MRNA--
The shipment marks a significant milestone in Canada's domestic vaccine production capacity and strengthens national health security [2]. Stéphane Bancel emphasized that the delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country is not just about local manufacturing but also about scientific leadership, national health security, and timely access to the latest mRNA medicines.
The drug substance of Moderna's authorized Spikevax® product is manufactured at the facility in Laval, Quebec, while the fill-and-finish of the new single-use pre-filled syringes is completed by Novocol Pharma in Cambridge, Ontario. The vaccine has also received authorization from regulators in the United States, Europe, Japan, Switzerland, and several other countries [2].
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, noted that this achievement represents a major step for Canada's biomanufacturing and life sciences sector. The government is building a resilient, forward-looking economy that positions Canada as a global leader in scientific research and innovation [2].
The Honourable Marjorie Michel, Minister of Health, highlighted that manufacturing the first-ever doses of a fully made-in-Canada COVID-19 vaccine demonstrates the power of collaboration between government, industry, and science to protect the health of Canadians. By producing vaccines locally, Canada supports its economy while strengthening its ability to respond quickly to future public health emergencies [2].
Canadian Access and Eligibility
Timing and eligibility for the COVID-19 public vaccination program in Canada are set by each province and territory. Those who meet provincial criteria will receive COVID-19 vaccines free of charge. For individuals not covered under the public programs, efforts are ongoing with private insurers and payers to streamline access and reimbursement within the private sector. Canadians are encouraged to consult their provincial or territorial health authorities for the latest information on eligibility and availability [2].
Moderna has shipped its first mRNA vaccines produced entirely in Canada to Canadian provinces and territories. The vaccines, targeting the SARS-CoV-2 LP.8.1 variant, were manufactured in Laval, Quebec, and filled in Cambridge, Ontario. The updated vaccine was approved by Health Canada on August 21, 2025, and has been authorized in several other countries. Moderna CEO Stéphane Bancel notes that this step enhances health security and ensures rapid access to the latest mRNA medicines.
Moderna has shipped its first mRNA vaccines produced entirely in Canada to Canadian provinces and territories. The vaccines, targeting the SARS-CoV-2 LP.8.1 variant, were manufactured in Laval, Quebec, and filled in Cambridge, Ontario. The updated vaccine was approved by Health Canada on August 21, 2025, and has been authorized in several other countries. Moderna CEO Stéphane Bancel notes that this step enhances health security and ensures rapid access to the latest mRNA medicines [1].The shipment marks a significant milestone in Canada's domestic vaccine production capacity and strengthens national health security [2]. Stéphane Bancel emphasized that the delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country is not just about local manufacturing but also about scientific leadership, national health security, and timely access to the latest mRNA medicines.
The drug substance of Moderna's authorized Spikevax® product is manufactured at the facility in Laval, Quebec, while the fill-and-finish of the new single-use pre-filled syringes is completed by Novocol Pharma in Cambridge, Ontario. The vaccine has also received authorization from regulators in the United States, Europe, Japan, Switzerland, and several other countries [2].
The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, noted that this achievement represents a major step for Canada's biomanufacturing and life sciences sector. The government is building a resilient, forward-looking economy that positions Canada as a global leader in scientific research and innovation [2].
The Honourable Marjorie Michel, Minister of Health, highlighted that manufacturing the first-ever doses of a fully made-in-Canada COVID-19 vaccine demonstrates the power of collaboration between government, industry, and science to protect the health of Canadians. By producing vaccines locally, Canada supports its economy while strengthening its ability to respond quickly to future public health emergencies [2].
Canadian Access and Eligibility
Timing and eligibility for the COVID-19 public vaccination program in Canada are set by each province and territory. Those who meet provincial criteria will receive COVID-19 vaccines free of charge. For individuals not covered under the public programs, efforts are ongoing with private insurers and payers to streamline access and reimbursement within the private sector. Canadians are encouraged to consult their provincial or territorial health authorities for the latest information on eligibility and availability [2].

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios